Joined November 2018
- Tweets 308
- Following 162
- Followers 79,659
- Likes 44
215 Photos and videos
Apr 11
At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: bit.ly/4voJn42
#BioNTech #WomensCancer #GynecologicOncology
3
27
2,500
Mar 26
Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.
1
2
12
2,031
Mar 26
The candidate is being developed by BioNTech and OncoC4.
Join the proffered paper session at 3:35 pm CET in Auditorium A1.
2
1,193
Mar 26
Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews
1
4
14
2,497
Mar 26
At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.
👉bit.ly/3NEw5zp
#nsclc #esclc
1
5
1,406
Jan 14
📢 JPM 2026|Strategic areas of focus
Oncology milestones in 2026:
- 7 late-stage data readouts
- 6 Phase 3 clinical trial initiations expected
- Focus on high-incidence indications, such as lung and breast cancer
📰 bit.ly/3YY5I9L
🎥 bit.ly/3YY5I9L
#JPM2026
5
29
4,297
11 Dec 2025
Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC.
Join the poster session at 12:30pm CST in Exhibit Hall.
3
21
3,608
10 Dec 2025
🔬 At #SABCS25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #TNBC with our partner @bmsnews
Learn more in our press release: bit.ly/48CnnrC
#BreastCancerResearch #OncologyScience #BioNTech
3
21
2,913
9 Dec 2025
Tomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L locally advanced/metastatic TNBC.
4
14
2,589
6 Dec 2025
Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC.
Learn more in our press release: bit.ly/4oGMM9U
#LungCancer #NACLC25
4
26
2,564
8 Sep 2025
Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25:
Investigational approach designed to target PD-L1 and VEGF-A in a single molecule.
Full PR: bit.ly/3I1dZVs
4
25
4,291
2 Jun 2025
We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 investors.biontech.de/news-r…
14
92
7,152
28 May 2025
At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies.
🗓 May 30 – June 3 | Chicago
📍 Booth #35165
#CancerResearch #ImmunoOncology #OncologyInnovation
1
8
37
4,487